Alume Biosciences, Inc.

About Alume Biosciences, Inc.

Alume Biosciences is dedicated to advancing precision surgery by developing nerve illumination technology to protect and preserve nerve function during surgical procedures. Their mission is to support surgeons in reducing nerve damage, thereby improving patient outcomes in surgeries such as head-and-neck and prostate surgeries.

Products & Services

Bevonescein (ALM-488):A breakthrough peptide in Phase 3 clinical trials, designed to make nerves glow during surgery for better visibility and safety. It is administered via IV before surgery, illuminates nerves during the procedure, and is cleared from the body post-surgery. Alume plans to submit a New Drug Application to the FDA in 2025.

Specialties

Nerve Illumination Technology Precision Surgery Surgical Safety Innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 13000000 MR: - FA: $13 million FAN: 13000000	D: 2023-01-10 FD: 2023-01-10	-

Series B Latest

2023-01-10

$13.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Q

Quyen Nguyen

Color-coded surgery

K

Kaveri Parker

Chief Business Officer

B

Brett Berman

Co-Founder and Chief Medical Officer

J

Jim Schmidt

Chief Financial Officer

R

Rick Gonzalez

Chief Commercial Officer

M

Marc Tokars

Executive Vice President of Clinical and Regulatory Affairs

View 11 more team members with Pro

Unlock Full Team Directory

Recent News